Exemestane

send to a friend share this

The potential clinical benefit of targeting androgen receptor (AR) in ER+ breast cancer cells treated with Exemestane

 

Authors and Afiliations:

Cristina Amaral, Tiago V. Augusto, Marta Almada, Sara C. Cunha, Georgina Correia-da-Silva, Natércia Teixeira

UCIBIO.REQUIMTE, Laboratório de Bioquímica, Faculdade de Farmácia, Universidade do Porto

 

Abstract: